

Clinical trials of tezosentan

TrialResults-center www.trialresultscenter.org

1 acute heart failure

Trial	Treatments	Patients	Trials design and methods
tezosentan vs placebo			
RITZ 4 import , 2003 n=193 follow-up: 72h	tezosentan (25 mg/h for 1 h, then 50 mg/h for 23 to 47 h) versus placebo	patients with acute heart failure associated with acute coronary syndrome	Parallel groups double-blind
RITZ-5 , 2003 n=84 follow-up: 24h	tezosentan (50 or 100 mg/h) for up to 24 h versus placebo	patients with acute congestive heart failure	Parallel groups double-blind
VERITAS I , 2006 [NCT00525707] n=730/718 follow-up: 7 days	Infusion of tezoesentan (5 mg/h for 30 minutes, followed by 1 mg/h for 24 to 72 hours) versus placebo	patients with acute heart failure	Parallel groups double-blind Australia, Europe, Israel, and North America.
VERITAS II , 2007 [NCT00525707] n=730/718 follow-up: 7 days	Tezosentan versus placebo	patients with acute heart failure admitted within the previous 24 hours with persisting dyspnea and a respiratory rate of 24/min or greater	Parallel groups double-blind Australia, Europe, Israel, and North America
tezosentan vs			
VERITAS 1 <i>ongoing</i> [NCT00525707] n=NA follow-up:	-	-	
VERITAS 2 <i>ongoing</i> [NCT00524433] n=NA follow-up:	-	-	

More details and results :

- new drug under development for acute heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q640>
- endothelin receptor antagonist for acute heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q643>

References

RITZ 4 import, 2003:

O'Connor CM, Gattis WA, Adams KF Jr, Shah MR, Kobrin I, Frey A, Gheorghiade M Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4). *Am Heart J* 2002;144:583-8 [[12360152](#)]

O'Connor CM, Gattis WA, Adams KF Jr, Hasselblad V, Chandler B, Frey A, Kobrin I, Rainisio M, Shah MR, Teerlink J, Gheorghiade M Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous Tezosentan Study (RITZ-4). *J Am Coll Cardiol* 2003;41:1452-7 [[12742280](#)]

O'Connor CM, Gattis WA, Adams KF Jr, Shah MR, Kobrin I, Frey A, Gheorghiade M Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4). *Am Heart J* 2002;144:583-8 [[12360152](#)]

RITZ-5, 2003:

Kaluski E, Kobrin I, Zimlichman R, Marmor A, Krakov O, Milo O, Frey A, Kaplan S, Krakover R, Caspi A, Vered Z, Cotter G RITZ-5: randomized intravenous Tezosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. *J Am Coll Cardiol* 2003;41:204-10 [[12535809](#)]

VERITAS I, 2006:

McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. *JAMA* 2007;298:2009-19 [[17986694](#)]

VERITAS II, 2007:

McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. *JAMA* 2007;298:2009-19 [[17986694](#)]

VERITAS 1, 0:

ongoing trial NCT00525707

VERITAS 2, 0:

ongoing trial NCT00524433